Ireland
--:--IST
Enrolling by invitation Not applicable

Clinical Efficacy of Jing Si Herbal Tea Liquid Packet to Treat Patients With Interstitial Cystitis/Bladder Pain Syndrome

NCT07927738 · tracked via the Priya Life Science Taiwan tracker
Phase
Not applicable
Started
2026-08-31
Last updated
2026-11-10

Condition(s) studied

Interstitial CystitisMultimodal Intervention

Investigational drug(s) / intervention(s)

Jing Si Herbal Tea liquid packet

Jing Si Herbal Tea liquid packet: The patients will be randomly assigned to receive intravesical IC therapy and placebo (control group) or concomitant IC treatment with Jing Si Herbal Tea liquid packet TID (treatment group) for 3 months. The voiding diary, ICSI, ICPI, VAS, PPBC, GRA, Qmax, Vol, and PVR are also investigated at baseline and after treatment, at 4 weeks, 8 weeks, 12 weeks, and 20 weeks after the treatment. The primary endpoint of this study is the improvement of GRA by 2 points at 12 weeks after treatment. The urinary biomarker levels will also be compared before baseline and after treatment.

Study summary

Introduction: Interstitial cystitis/bladder pain syndrome (IC/BPS) is a disease of unknown etiology, with clinical characteristics of bladder pain, frequency, urgency, and nocturia. There has been no effective and durable medication to cure this disease. Current research has revealed that chronic bladder wall inflammation and bladder mucosal denudation are the fundamental pathology for clinical symptoms. Using Jing Si Herbal Tea liquid packets may have a therapeutic effect in patients with refractory IC/BPS.

Aim: To investigate the effect of Jing Si Herbal Tea liquid packet intervention added to urological therapy for patients with refractory IC/BPS.

Materials and Methods: This study will enroll patients with IC/BPS who are refractory to various conventional treatments after cystoscopic hydrodistention, antimuscarinic, and painkiller treatments. These patients plan to receive further intravesical IC therapy, such as intravesical hyaluronic acid (HA) instillation, intravesical botulinum toxin A (Botox) injection, intravesical platelet-rich plasma (PRP) injection, or low-energy shock wave (LESW) therapy. The patients will be randomly assigned to receive intravesical IC therapy and placebo (control group) or concomitant IC treatment with Jing Si Herbal Tea liquid packet TID (treatment group) for 3 months. The voiding diary, ICSI, ICPI, VAS, PPBC, GRA, Qmax, Vol, and PVR are also assessed at baseline and at 4, 12, and 20 weeks after treatment. The primary endpoint of this study is the improvement of GRA by 2 points at 12 weeks after treatment.

Assessment: The patients will be investigated using the voiding diary (for frequency of nocturia episodes per day), ICSI, IC problem index (ICPI), Numerical Rating Scale (NRS) of pain, patient perception of bladder condition (PPBC), global response assessment (GRA), maximal flow rate (Qmax), voided volume (Vol), and post-void residual urine (PVR) volume measurement at baseline and after treatment. Urine samples will also be obtained for determination of urinary biomarkers at baseline and after different therapies.

Eligibility

Sex
ALL
Min age
20 Years
Max age
84 Years
Healthy volunteers
No
Inclusion Criteria: * This study is expected to select patients with IC (non-ulcer type, Glomerulation \>1, interstitial cystitis symptom index (ICSI≧12 points) in the urology outpatient clinic, and use anticholinergic drugs and pain medication treatment. The symptoms have not improved significantly (ICSI≧12). Patients will be asked about their willingness before being selected to confirm that they are willing to accept this clinical trial, and they can be included in this clinical trial after completing the entire course of the treatment test. Exclusion Criteria: 1. non-IC/BPS patients 2. psychological disease was diagnosed 3. non-NIDDK criteria (Hunner\'s ulcer type) 4. Under-primary or illiterate respondents 5. patients with severe cardiopulmonary disease and such as congestive heart failure, arrhythmia, poorly controlled hypertension, not able to receive regular follow up 6. Patients with bladder outlet obstruction on enrollment 7. Patients with post-void residual \> 150ml 8. Patients with an uncontrolled confirmed diagnosis of acute urinary tract infection 9. Patients have laboratory abnormalities at screening including: ALT\> 3 x upper limit of normal range AST\> 3 x upper limit of normal range Patients have abnormal serum creatinine level \>2 x upper limit of normal range 10. Patients who cannot used urinary catheter to treat. 11. Female patients who are pregnant, lactating, or childbearing potential without contraception. 12. Patients with any other serious disease considered by the investigator not in the condition to enter the trial 13. Patients cannot record the voiding diary

Primary outcome measure(s)

  • Global Response Assessment (GRA) at Week 12 — Week 12
    The Global Response Assessment (GRA) evaluates patient-reported overall changes in bladder symptoms following treatment. Higher scores indicate greater perceived improvement.

Trial sites (1)

FacilityCityRegionStatus
Hualien Tzu Chi General Hospital, Tzu Chi Medical Foundation Hualien City Taiwan
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07927738 on ClinicalTrials.gov ↗ ← All trials in Taiwan